[go: up one dir, main page]

WO2008152822A1 - Medicinal agent - Google Patents

Medicinal agent Download PDF

Info

Publication number
WO2008152822A1
WO2008152822A1 PCT/JP2008/001535 JP2008001535W WO2008152822A1 WO 2008152822 A1 WO2008152822 A1 WO 2008152822A1 JP 2008001535 W JP2008001535 W JP 2008001535W WO 2008152822 A1 WO2008152822 A1 WO 2008152822A1
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
agent
medicinal
therapeutic agent
antibody therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/001535
Other languages
French (fr)
Japanese (ja)
Inventor
Andrew Nicol
Hirotake Tokuyama
Tomomi Hagi
Mie Nieda
Masato Muto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medinet Co Ltd
Original Assignee
Medinet Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinet Co Ltd filed Critical Medinet Co Ltd
Priority to JP2009519171A priority Critical patent/JPWO2008152822A1/en
Publication of WO2008152822A1 publication Critical patent/WO2008152822A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed are: a medicinal agent which enables to improve the ADCC which occurs in vivo upon the administration of a monoclonal antibody therapeutic agent; a therapeutic/prophylactic method; and an adjuvant for improving the effect of a monoclonal antibody therapeutic agent. A combination of a ϜδT cell activated and/or proliferated with a bisphosphonate and IL-2 and a monoclonal antibody therapeutic agent can be used as a medicinal agent. The medicinal agent exhibits its medicinal effect synergistically at a higher level compared to a case where each of the ϜδT cell and the monoclonal antibody therapeutic agent isused singly.
PCT/JP2008/001535 2007-06-15 2008-06-13 Medicinal agent Ceased WO2008152822A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009519171A JPWO2008152822A1 (en) 2007-06-15 2008-06-13 Medicine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007159398 2007-06-15
JP2007-159398 2007-06-15

Publications (1)

Publication Number Publication Date
WO2008152822A1 true WO2008152822A1 (en) 2008-12-18

Family

ID=40129436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/001535 Ceased WO2008152822A1 (en) 2007-06-15 2008-06-13 Medicinal agent

Country Status (2)

Country Link
JP (1) JPWO2008152822A1 (en)
WO (1) WO2008152822A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010063847A1 (en) * 2008-12-04 2010-06-10 Universite Victor Segalen Bordeaux 2 Compositions for potentiating apoposis signals in tumour cells
WO2013174509A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP2015522543A (en) * 2012-05-23 2015-08-06 ガニメド ファーマシューティカルズ アーゲー Combination therapy with antibodies to claudin 18.2 to treat cancer
WO2016005752A1 (en) * 2014-07-09 2016-01-14 Tc Biopharm Ltd Gamma delta t cells and uses thereof
JP2016510721A (en) * 2013-02-20 2016-04-11 ガニメド ファーマシューティカルズ アーゲー Combination therapy involving antibodies to claudin 18.2 for the treatment of cancer
US9751934B2 (en) 2005-11-24 2017-09-05 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US10137195B2 (en) 2013-03-18 2018-11-27 Ganymed Pharmaceuticals Gmbh Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US10881688B2 (en) 2015-04-15 2021-01-05 Tc Biopharm Ltd Modified gamma delta T cells and uses thereof
EP4119582A1 (en) * 2012-05-23 2023-01-18 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US12331316B2 (en) 2015-04-30 2025-06-17 Ucl Business Ltd T cell which expresses a gamma-delta t cell receptor (TCR) and a chimeric antigen receptor (CAR)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030223998A1 (en) * 2002-02-27 2003-12-04 Lamb Lawrence S. Targeted immunotherapy of acute lymphoblastic leukemia (ALL)
JP2004529102A (en) * 2000-10-24 2004-09-24 イミュネックス・コーポレーション How to use combination therapy to treat tumors
WO2006006720A1 (en) * 2004-07-13 2006-01-19 Medinet., Co.Ltd METHOD OF CULTURING ϜδT CELLS, ϜδT CELLS AND REMEDY/PREVENTIVE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004529102A (en) * 2000-10-24 2004-09-24 イミュネックス・コーポレーション How to use combination therapy to treat tumors
US20030223998A1 (en) * 2002-02-27 2003-12-04 Lamb Lawrence S. Targeted immunotherapy of acute lymphoblastic leukemia (ALL)
WO2006006720A1 (en) * 2004-07-13 2006-01-19 Medinet., Co.Ltd METHOD OF CULTURING ϜδT CELLS, ϜδT CELLS AND REMEDY/PREVENTIVE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERRINI S. ET AL.: "Retargeting of T-cell-receptor gamma/delta-pos. lymphocytes against tumor cells by bispecific monoclonal antibodies. Induction of cytolytic activity and lymphokine production", INTERNATIONAL JOURNAL OF CANCER, no. SUPPL. 4, 1989, pages 53 - 55 *
ROSSI J.-F. ET AL.: "Enhancing lysis of B cell lymphoma by innovative gamma delta T cell immunotherapies using agonist IPH1101 (phosphotim, BrHPP)", BLOOD, vol. 108, no. 11, 2006, pages 391B, XP008083238 *

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US11739139B2 (en) 2005-11-24 2023-08-29 Astellas Pharma Inc. Monoclonal antibodies against Claudin-18 for treatment of cancer
US10738108B2 (en) 2005-11-24 2020-08-11 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
US10174104B2 (en) 2005-11-24 2019-01-08 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US10017564B2 (en) 2005-11-24 2018-07-10 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US9751934B2 (en) 2005-11-24 2017-09-05 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
FR2939314A1 (en) * 2008-12-04 2010-06-11 Univ Victor Segalen Bordeaux 2 NOVEL COMPOSITIONS AND METHODS FOR THE POTENTIATION OF APOPTOSIS SIGNALS IN TUMOR CELLS
WO2010063847A1 (en) * 2008-12-04 2010-06-10 Universite Victor Segalen Bordeaux 2 Compositions for potentiating apoposis signals in tumour cells
US12059464B2 (en) 2012-05-23 2024-08-13 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10022444B2 (en) 2012-05-23 2018-07-17 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
KR20200140387A (en) * 2012-05-23 2020-12-15 가니메드 파마슈티칼스 게엠베하 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
KR102514338B1 (en) 2012-05-23 2023-03-28 가니메드 파마슈티칼스 게엠베하 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP2015522543A (en) * 2012-05-23 2015-08-06 ガニメド ファーマシューティカルズ アーゲー Combination therapy with antibodies to claudin 18.2 to treat cancer
CN107412773A (en) * 2012-05-23 2017-12-01 加尼梅德药物公司 The therapeutic alliance for being related to the antibody for claudin 18.2 for treating cancer
AU2013265637B2 (en) * 2012-05-23 2017-12-21 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
JP2018002724A (en) * 2012-05-23 2018-01-11 ガニメド ファーマシューティカルズ ゲーエムベーハー Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP2018035155A (en) * 2012-05-23 2018-03-08 ガニメド ファーマシューティカルズ ゲーエムベーハー Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2013265637B8 (en) * 2012-05-23 2018-04-26 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
JP2015518838A (en) * 2012-05-23 2015-07-06 ガニメド ファーマシューティカルズ アーゲー Combination therapy with antibodies to claudin 18.2 to treat cancer
US9433675B2 (en) 2012-05-23 2016-09-06 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
KR102188001B1 (en) 2012-05-23 2020-12-07 가니메드 파마슈티칼스 게엠베하 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP2023038230A (en) * 2012-05-23 2023-03-16 アステラス製薬株式会社 Combination therapy with antibodies against claudin 18.2 to treat cancer
CN104427999A (en) * 2012-05-23 2015-03-18 加尼梅德药物公司 Combination therapy involving antibodies against claudin 18.2 for the treatment of cancer
KR20150027112A (en) * 2012-05-23 2015-03-11 가니메드 파마슈티칼스 아게 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP4119582A1 (en) * 2012-05-23 2023-01-18 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP2019104747A (en) * 2012-05-23 2019-06-27 ガニメド ファーマシューティカルズ ゲーエムベーハー Combination therapy with antibodies against claudin 18.2 to treat cancer
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2018201856B2 (en) * 2012-05-23 2020-06-18 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
WO2013174509A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN107412773B (en) * 2012-05-23 2021-04-06 加尼梅德药物公司 Combination therapy involving antibodies against claudin 18.2 for the treatment of cancer
US10813996B2 (en) 2012-05-23 2020-10-27 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
JP2018197260A (en) * 2013-02-20 2018-12-13 ガニメド ファーマシューティカルズ ゲーエムベーハー Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US9770487B2 (en) 2013-02-20 2017-09-26 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma
US10946069B2 (en) 2013-02-20 2021-03-16 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
JP2020125329A (en) * 2013-02-20 2020-08-20 ガニメド ファーマシューティカルズ ゲーエムベーハー Combination therapy comprising antibodies against claudin 18.2 for the treatment of cancer
JP7051931B2 (en) 2013-02-20 2022-04-11 ガニメド ファーマシューティカルズ ゲーエムベーハー Combination therapy with antibodies to claudin 18.2 for the treatment of cancer
JP2022088550A (en) * 2013-02-20 2022-06-14 ガニメド ファーマシューティカルズ ゲーエムベーハー Combination therapy with antibodies to claudin 18.2 for the treatment of cancer
JP7681061B2 (en) 2013-02-20 2025-05-21 アステラス製薬株式会社 Combination Therapies Comprising Antibodies Against Claudin 18.2 for the Treatment of Cancer - Patent application
US10314890B2 (en) 2013-02-20 2019-06-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
US11826402B2 (en) 2013-02-20 2023-11-28 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma
JP2023123596A (en) * 2013-02-20 2023-09-05 ガニメド ファーマシューティカルズ ゲーエムベーハー Combination therapy comprising antibodies against claudin 18.2 for the treatment of cancer
JP7299369B2 (en) 2013-02-20 2023-06-27 ガニメド ファーマシューティカルズ ゲーエムベーハー Combination therapy comprising antibodies against claudin 18.2 for the treatment of cancer
JP2016510721A (en) * 2013-02-20 2016-04-11 ガニメド ファーマシューティカルズ アーゲー Combination therapy involving antibodies to claudin 18.2 for the treatment of cancer
US10137195B2 (en) 2013-03-18 2018-11-27 Ganymed Pharmaceuticals Gmbh Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US11395852B2 (en) 2013-03-18 2022-07-26 Astellas Pharma Inc. Therapy involving antibodies against Claudin 18.2 for treatment of cancer
WO2016005752A1 (en) * 2014-07-09 2016-01-14 Tc Biopharm Ltd Gamma delta t cells and uses thereof
US10881688B2 (en) 2015-04-15 2021-01-05 Tc Biopharm Ltd Modified gamma delta T cells and uses thereof
US12331316B2 (en) 2015-04-30 2025-06-17 Ucl Business Ltd T cell which expresses a gamma-delta t cell receptor (TCR) and a chimeric antigen receptor (CAR)

Also Published As

Publication number Publication date
JPWO2008152822A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
WO2008152822A1 (en) Medicinal agent
WO2009099719A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
MX2022003132A (en) Orally administered corticosteroid compositions.
WO2008113834A3 (en) C5 antigens and uses thereof
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
WO2009089494A3 (en) Pharmaceutical compositions
NZ620326A (en) Cd37 immunotherapeutic combination therapies and uses thereof
MX2010005676A (en) Method of delaying the onset of clinically definite multiple sclerosis.
WO2012015741A3 (en) Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
WO2010132882A3 (en) Sublingual dexmedetomidine compositions and methods of use thereof
WO2007127273A3 (en) Methods and compositions for altering cell function
UA96076C2 (en) Use of trans-clomiphene
MX339116B (en) Tuberous sclerosis treatment.
WO2009114703A3 (en) Combination therapy for the treatment of cancer
WO2007100561A3 (en) Use of dha and ara in the preparation of a composition for preventing or treating obesity
NZ598722A (en) Methods for treating psoriasis
NZ578065A (en) Methods for treating psoriasis with an antibody which binds to an epitope
WO2008016730A3 (en) Compositions and methods for reducing cellular fat
WO2011075822A8 (en) Immunogenic compositions and related methods
WO2015003122A3 (en) Regulation of glucose metabolism using anti-cgrp antibodies
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
EP2152232A4 (en) Methods and compositions for administration of oxybutynin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08764130

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009519171

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08764130

Country of ref document: EP

Kind code of ref document: A1